Nutriband Inc.

NasdaqCM NTRB

Nutriband Inc. EBIT for the Trailing 12 Months (TTM) ending October 31, 2024: USD -6.81 M

Nutriband Inc. EBIT is USD -6.81 M for the Trailing 12 Months (TTM) ending October 31, 2024, a -29.72% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Nutriband Inc. EBIT for the Trailing 12 Months (TTM) ending October 31, 2023 was USD -5.25 M, a 19.98% change year over year.
Nutriband Inc. EBIT for the Trailing 12 Months (TTM) ending October 31, 2022 was USD -6.56 M, a -46.66% change year over year.
Nutriband Inc. EBIT for the Trailing 12 Months (TTM) ending October 31, 2021 was USD -4.47 M, a -232.17% change year over year.
Nutriband Inc. EBIT for the Trailing 12 Months (TTM) ending October 31, 2020 was USD -1.35 M, a 40.68% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: NTRB

Nutriband Inc.

CEO	Mr. Gareth Sheridan
IPO Date	Oct. 1, 2021
Location	United States
Headquarters	121 South Orange Avenue
Employees	13
Sector	Health Care
Industries Pharmaceuticals

Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Key trends

Past 5 years